-
公开(公告)号：US11517741B2
公开(公告)日：2022-12-06
申请号：US16077979
申请日：2017-02-02
IPC分类号： A61N1/04
摘要： An electrode for electroporation comprising a plurality of electrode needles, wherein first polarity electrode needles, an electrode needle holding portion, and a syringe holding portion are provided; two or more first polarity electrode needles project from a bottom surface of a lower structural body of an outer frame support of the electrode needle holding portion toward an electroporation target side; the bottom surface of the lower structural body of the outer frame support is provided with a hole for syringe needle insertion and removal communicating with a syringe holding portion side; the syringe holding portion is provided on a side opposite to the electroporation target side of the electrode needle holding portion; and the syringe holding portion has a path for syringe needle insertion and removal, at least a portion of the path for syringe needle insertion and removal being provided with an electro-conductive portion for a second polarity.
-
公开(公告)号：US20220144905A1
公开(公告)日：2022-05-12
申请号：US17271088
申请日：2019-08-28
发明人： Kiyoshi OGURA
摘要： The present invention aims to provide a peptide of the C region of HGS and an antitumor agent comprising the same having a higher tumor growth inhibitory effect as compared with conventional techniques.
The present invention provides an antitumor agent comprising a peptide comprising at least 10 consecutive amino acid residues of the amino acid sequence of the C region of HGS.-
公开(公告)号：US20170357750A1
公开(公告)日：2017-12-14
申请号：US15645739
申请日：2017-07-10
CPC分类号： G16B20/00 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The present invention provides a method for evaluating (predicting, etc.) an individual difference (the tendency of every individual) in terms of drug sensitivity and disease vulnerability, comprising using a gene polymorphism of a cyclic AMP responsive element binding protein gene or the like. The method for evaluating drug sensitivity and the method for evaluating disease vulnerability according to the present invention comprise associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with the drug sensitivity and disease vulnerability of an individual.
-
4.发明授权Polynucleotides encoding proteins having acquired α-galactosidase activity 有权编码具有获得性α-半乳糖苷酶活性的蛋白质的多核苷酸公开(公告)号：US09315790B2
公开(公告)日：2016-04-19
申请号：US14026471
申请日：2013-09-13
CPC分类号： C12N9/2465 , A61K38/47 , A61K48/005
摘要： The present invention provides a pharmaceutical composition comprising a protein having α-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an α-galactosidase activity through alteration of the structure of the active site of wild-type human α-N-acetylgalactosaminidase.
摘要翻译： 本发明提供一种药物组合物，其包含具有α-半乳糖苷酶活性的蛋白质，用于治疗法布里病，其不引起过敏性副作用，其在血液（血浆）中高度稳定，并且可容易地被受影响器官的细胞摄取 。 用于治疗本发明的法布里病的药物组合物包括例如通过改变野生型人α-N-乙酰半乳糖胺酶的活性位点的结构而获得α-半乳糖苷酶活性的蛋白质。
-
5.发明授权公开(公告)号：US09090681B2
公开(公告)日：2015-07-28
申请号：US13910544
申请日：2013-06-05
CPC分类号： G01N33/57438 , C07K14/47 , C07K16/18 , C07K16/44 , C07K2317/34 , C12Q1/485 , G01N33/57496 , G01N33/68 , G01N2333/4703 , G01N2440/14 , G01N2500/02
摘要： The present invention provides antibodies useful for diagnosing and treating tumors as well as methods of screening for antitumor agents. More specifically, tumors can be diagnosed and treated using an anti-phosphorylated p62 antibody that recognizes phosphorylation of serine at position 351 of an amino acid sequence of SEQ ID No. 1 or at a position corresponding thereto. An antitumor agent can be obtained by screening for a substance that inhibits the phosphorylation or that dephosphorylates the phosphorylated serine.
摘要翻译： 本发明提供了可用于诊断和治疗肿瘤的抗体以及筛选抗肿瘤剂的方法。 更具体地，可以使用识别SEQ ID No.1的氨基酸序列的351位丝氨酸的磷酸化的抗磷酸化p62抗体或与其对应的位置来诊断和治疗肿瘤。 可通过筛选抑制磷酸化的物质或使磷酸化丝氨酸脱磷酸化获得抗肿瘤剂。
-
公开(公告)号：US09000136B2
公开(公告)日：2015-04-07
申请号：US12736079
申请日：2009-03-06
申请人： Michinori Kohara , Fukashi Murai
发明人： Michinori Kohara , Fukashi Murai
IPC分类号： C07H21/02 , C12Q1/70 , A61K39/29 , C12N15/863 , A61K39/00
CPC分类号： C12N15/8636 , A01K67/0275 , A01K2217/15 , A01K2217/203 , A01K2267/0337 , A61K35/13 , A61K39/12 , A61K39/29 , A61K2039/525 , A61K2039/5256 , A61K2039/57 , C07K14/005 , C12N15/8509 , C12N2710/24143 , C12N2770/24222 , C12N2770/24234
摘要： Provided is a recombinant virus which is efficacious in preventing the onset of hepatitis C infection and has a high safety. Also provided is a vaccine for hepatitis C virus which contains the recombinant virus. A recombinant vaccinia virus which can express hepatitis C virus gene. The hepatitis C virus vaccine as described above contains the recombinant virus as described above.
摘要翻译： 提供一种重组病毒，其有效预防丙型肝炎感染的发生并具有高安全性。 还提供了含有重组病毒的丙型肝炎病毒疫苗。 可以表达丙型肝炎病毒基因的重组痘苗病毒。 如上所述的丙型肝炎病毒疫苗含有如上所述的重组病毒。
-
7.发明授权Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus 有权能够抑制丙型肝炎病毒活性的寡核苷酸或肽核酸公开(公告)号：US08957199B2
公开(公告)日：2015-02-17
申请号：US13130673
申请日：2009-11-26
申请人： Michinori Kohara , Masayuki Sudo
发明人： Michinori Kohara , Masayuki Sudo
IPC分类号： C07H21/04 , C12N15/11 , C12N15/113
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2320/11
摘要： The present inventors focused on siE sequences that have been thought to show RNAi activity against HCV viral RNAs, and mainly selected the D5-50 and D5-197 regions present within the IRES region, and carried on the analysis. As a result, the present inventors successfully identified siRNA sequences that exhibit a more effective RNAi activity against hepatitis C virus RNAs. Furthermore, the siRNAs were demonstrated to have a significant inhibitory effect on HCV propagation in an in vivo system.
摘要翻译： 本发明人着重于已被认为显示针对HCV病毒RNA的RNAi活性的siE序列，主要选择存在于IRES区域内的D5-50和D5-197区域，并进行分析。 结果，本发明人成功地鉴定了对丙型肝炎病毒RNA表现出更有效的RNAi活性的siRNA序列。 此外，证实siRNA在体内系统中对HCV繁殖具有显着的抑制作用。
-
公开(公告)号：US08940872B2
公开(公告)日：2015-01-27
申请号：US12667624
申请日：2008-07-07
CPC分类号： C07K16/18 , G01N33/6875
摘要： The present invention provides an antibody that specifically binds to an abnormal TDP-43 protein aggregate, an agent comprising the antibody for detecting a TDP-43 proteinopathy lesion, and a method for detecting or diagnosing a TDP-43 proteinopathy lesion by using the antibody.
摘要翻译： 本发明提供特异性结合异常TDP-43蛋白质聚集体的抗体，包含用于检测TDP-43蛋白病变病变的抗体的试剂，以及使用该抗体检测或诊断TDP-43蛋白病变病变的方法。
-
公开(公告)号：US08715643B2
公开(公告)日：2014-05-06
申请号：US12936585
申请日：2009-03-06
CPC分类号： G01N33/5058 , C07K14/4711 , G01N33/5014
摘要： Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene.
摘要翻译： 公开了一种转化细胞（细胞模型），其可以形成来自患有神经变性疾病如FTLD的患者的脑中的43kDa（TDP-43）的TAR DNA结合蛋白的细胞质包涵体，以及 ALS。 转化细胞的特征在于在其中引入能够在宿主细胞中起作用的启动子和突变型TDP-43基因。
-
公开(公告)号：US20140044699A1
公开(公告)日：2014-02-13
申请号：US14026471
申请日：2013-09-13
IPC分类号： C12N9/40
CPC分类号： C12N9/2465 , A61K38/47 , A61K48/005
摘要： The present invention provides a pharmaceutical composition comprising a protein having α-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an α-galactosidase activity through alteration of the structure of the active site of wild-type human α-N-acetylgalactosaminidase.
摘要翻译： 本发明提供了一种药物组合物，其包含具有用于治疗法布里病的α-半乳糖苷酶活性的蛋白质，其不引起过敏性副作用，其在血液（血浆）中高度稳定并且可容易地被受影响器官的细胞摄取 。 用于治疗本发明的法布里病的药物组合物包括例如通过改变野生型人α-N-乙酰半乳糖胺酶的活性位点的结构获得α-半乳糖苷酶活性的蛋白质。
-
-
-
-
-
-
-
-
-
搜索结果
82 条记录 (耗时 0.04 秒)
